Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis

Inclusion Criteria: * Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week * Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs * Extent of scalp psoriasis involving more than 10% of the total scalp area * Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity Exclusion Criteria: * PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation * UVB therapy anywhere on the patient within 14 days prior to randomisation * Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton * Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation * Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton * Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation * Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study * Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis * Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin * Known or suspected severe renal insufficiency or severe hepatic disorders * Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia * Trial subjects should be using an adequate method of contraception